Login Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis Zrubka, Zsombor and Gulácsi, László and Brodszky, Valentin and Rencz, Fanni and Alten, Rieke and Szekanecz, Zoltán and Péntek, Márta Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis.
Abstract Introduction: Early biological treatment of rheumatoid arthritis RA may reverse the autoimmune response in some patients resulting in favorable long-term outcomes.
Although the cost-effectiveness of this strategy has been questioned, biosimilar entries warrant the revision of clinical and pharmaco-economic evidence. We performed meta-analyses for efficacy csukló-rándulások kezelése at month 6 and years 1 and 2. Six RCTs were identified, involving patients.
Gut Bacteria Hold Potential for Treating Rheumatoid Arthritis, Mayo Study Finds
The differences were not significant at year 2. Four studies rheumatoid arthritis treatment research that first-line use of originator infliximab calculated at — prices was not cost-effective.
Expert opinion: We demonstrated the efficacy benefits of first-line infliximab therapy up to 1 year in methotrexate-naïve RA. We highlighted the need for standardized reporting of outcomes and conducting cost-effectiveness analyses of first-line biosimilar therapy in RA.